Sales & Marketing News | pharmaphorum

News

Fabhalta is first FDA-approved therapy for rare disease C3G

Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.

News

J&J adds to IL-23 options in Crohn's after FDA approval

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

News

UK is becoming an 'outlier' for pharma, hitting investment

UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.

News

Novartis sheds staff as Entresto patent expiry looms

Novartis will cut 427 jobs this year in the US as it prepares for the loss of market exclusivity for its blockbuster heart failure therapy Entresto.

News

Novo Nordisk returns to ABPI fold after two-year suspension

Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."

News

FDA chooses flu vaccine strains despite cancelled meeting

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.

Fabhalta is first FDA-approved therapy for rare disease C3G

J&J adds to IL-23 options in Crohn's after FDA approval

UK is becoming an 'outlier' for pharma, hitting investment

Novartis sheds staff as Entresto patent expiry looms

Novo Nordisk returns to ABPI fold after two-year suspension

FDA chooses flu vaccine strains despite cancelled meeting

AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks